Supplementary Material

Repeated Sigma-1 receptor antagonist MR309 administration modulates central neuropathic pain development after spinal cord injury in mice

Silvia Castany\textsuperscript{a,b}, Xavier Codony\textsuperscript{b}, Daniel Zamanillo\textsuperscript{b}, Manuel Merlos\textsuperscript{b}, Enrique Verdú\textsuperscript{a,1}, and Pere Boadas-Vaello\textsuperscript{a,1,*}

\textsuperscript{a} Research Group of Clinical Anatomy, Embryology and Neuroscience (NEOMA), Department of Medical Sciences, Universitat de Girona (UdG), Girona, Spain.

\textsuperscript{b} Esteve Pharmaceuticals, Drug Discovery and Preclinical Development, Parc Científic de Barcelona, Barcelona, Spain.

\textsuperscript{1} Authors Pere Boadas-Vaello and Enrique Verdú Navarro contributed equally to this work

\* Correspondence: Pere Boadas Vaello : pere.boadas@udg.edu
Supplementary Figures

**Supplementary Figure S1.** Original scanned full blots for pERK, tERK and GAPDH shown in Figure 2 A,B.
Supplementary Figure S2. Original scanned full blots for Y1472 and S1303 phosphorylation of NR2B, NR2B total and GAPDH shown in Figure 3 A,B,C,D.
Supplementary Figure S3. Original scanned full blots for TNF-α, IL1β and GAPDH shown in Figure 4 A,B,C,D.